Indobell Insul. (544334)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 1/1

Key Financials

Strengths

• ROCE of 23.71% signals strong capital efficiency and a possible niche advantage.
• Sales growth of 26.35% shows healthy demand, with profit growth of 14.29% still positive.
• Piotroski F-Score of 7/9 suggests sound operational health.
• Dividend yield of 3.42% offers some cash return at a reasonable valuation.
• P/E of 16.47 combined with a PEG of 0.81 appears reasonably priced if growth sustains.

Concerns

• Latest quarter net profit is reported as ₹0 Cr on ₹7 Cr sales, indicating severe quarterly margin weakness.
• Profit growth of 14.29% lags sales growth of 26.35%, implying margin compression.
• Critical data missing: book value, debt/equity, promoter holding, and FairStock score are not available.
• Market cap of only ₹37 Cr makes the stock very small, illiquid, and vulnerable to sharp swings.

AI Analysis

Indobell Insul. is the kind of small industrial name I would look at with cautious interest. The 23.71% ROCE is a genuinely good number; it implies the business can convert capital employed into profits efficiently, which often points to a niche advantage. Sales have risen 26.35%, and profit growth is 14.29%. That combination makes the company look like a fast grower, but I want my portfolio to earn growing profits, not just growing revenues. The latest quarter reports ₹7 Cr sales but virtually no net profit—that is a red flag. Annual earnings may justify a P/E of 16.47, but quarterly profit has collapsed to zero, so I must ask whether margins are under structural pressure or just suffering bad timing. The PEG of 0.81 seems attractive, but it appears to assume faster earnings growth than the 14.29% actually shown; I prefer to trust the real growth number. The Piotroski score of 7/9 gives some confidence that fundamentals are not deteriorating, and the 3.42% dividend yield is a modest compensation while I wait. However, as a Graham disciple, I need a margin of safety. Here I am handicapped: book value, debt/equity and promoter holding are not available, and the FairStock score itself says insufficient data. A ₹37 Cr market cap is tiny; one large order, or one lost customer, can move the needle violently. I will not pay a premium without audited evidence of stable margins and better disclosure. If the next few quarters show net profit recovering and margin expansion, this small compounder could be interesting. Until then, it remains a show-me story: wonderful ROCE, good sales growth, but uncertain near-term profitability.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer